Detection of disseminatedtumor cells: Strategies and diagnostic implications

Expert Review of Molecular Diagnostics

Volumn 2, Issue 1, 2002, Pages 41-48

  Zehentner, Barbara k ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

circulating tumor cells; disseminated tumor cells; micrometastases; minimal residual disease; tumor markers

Indexed keywords

BLOOD CELL; BONE MARROW; CHEMISTRY; CYTOLOGY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; NEOPLASM; PATHOLOGY; REVIEW; TUMOR EMBOLISM; BLOOD ANALYSIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC APPROACH ROUTE; HISTOLOGY; IMMUNOLOGY; MINIMAL RESIDUAL DISEASE; PROGNOSIS; SOLID TUMOR; TUMOR CELL;

BLOOD CELLS; BONE MARROW; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASMS; HUMAN;

BIOLOGICAL MARKER; DNA MARKER;

EID: 0035998304     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2.1.41     Document Type: Review

References (84)

1. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymphnode metastases in the management of breast cancer. International Breast Cancer Study Group. Lancet 354 (9182), 896–900 (1999).
2. Brugger W, Buhring HJ, Grunebach F et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J. Clin. Oncol. 17 (5), 1535–1544 (1999).
3. Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med. Oncol. 16 (3), 154–165 (1999).
4. Muller P, Schlimok G. Bone marrow micrometastases of epithelial tumors: detection and clinical relevance. J. Cancer Res. Clin. Oncol. 126 (11), 607–618 (2000).
5. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342 (8), 525–533 (2000).
6. Borgen E, Beiske K, Trachsel S et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: nonspecific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J. Pathol. 185 (4), 427–434 (1998).
7. Borgen E, Naume B, Nesland J et al. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 46 (4), 215–221 (2001).
8. Bauer KD, Torre-Bueno J, Diel IJ et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin. Cancer Res. 6 (9), 3552–3559 (2000).
9. von Knebel Doeberitz M, Weitz J, Koch M et al. Molecular tools in the detection of micrometastatic cancer cells technical aspects and clinical relevance. Recent Results Cancer Res. 158, 181–186 (2001).
10. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5 (8), 1950–1960 (1999).
11. Hayashi N, Ito I, Yanagisawa A et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345 (8960), 1257–1259 (1995).
12. Hashimoto T, Kobayashi Y, Ishikawa Y et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res. 60 (22), 6472–6478 (2000).
13. Sanchez-Cespedes M, Esteller M, Hibi K et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin. Cancer Res. 5 (9), 2450–2454 (1999).
14. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60 (21), 5941–5945 (2000).
15. Capone RB, Pai SI, Koch WM et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6 (11), 4171–4175 (2000).
16. Taback B, Fujiwara Y, Wang HJ et al. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 61 (15), 5723–5726 (2001).
17. Engel H, Kleespies C, Friedrich J et al. Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics. Br. J. Cancer 81 (7), 1165–1173 (1999).
18. Silva JM, Dominguez G, Silva J et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin. Cancer Res. 7 (9), 2821–2825 (2001).
19. Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol. 12 (4), 725–729 (1994).
20. Guadagni F, Kantor J, Aloe S et al. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Cancer Res. 61 (6), 2523–2532 (2001).
21. Miyashiro I, Kuo C, Huynh K et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin. Chem. 47 (3), 505–512 (2001).
22. Hautkappe AL, Lu M, Mueller H et al. Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for -fetoprotein-messenger RNA and human chorionic gonadotropin-messenger RNA. Cancer Res. 60 (12), 3170–3174 (2000).
23. Hoon DS, Sarantou T, Doi F et al. Detection of metastatic breast cancer by - hCG polymerase chain reaction. Int. J. Cancer 69 (5), 369–374 (1996).
24. de Cremoux P, Extra JM, Deni MG et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin. Cancer Res. 6 (8), 3117–3122 (2000).
25. Millon R, Jacqmin D, Muller D et al. Detection of prostate-specific antigen- or prostate-specific membrane antigenpositive circulating cells in prostatic cancer patients: clinical implications. Eur. Urol. 36 (4), 278–285 (1999).
26. Soeth E, Vogel I, Roder C et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res. 57 (15), 3106–3110 (1997).
27. Slade MJ, Smith BM, Sinnett HD, Croxx NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J. Clin. Oncol. 17 (3), 870–879 (1999).
28. Weitz J, Kienle P, Magener A et al. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin. Cancer Res. 5 (7), 1830–1836 (1999).
29. Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanomarelated transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results Cancer Res. 15863– 15877 (2001).
30. Alao JP, Mohammed MQ, Slade MJ, Retsas S. Detection of tyrosinase mRNA by RTPCR in the peripheral blood of patients with advanced metastatic melanoma. Melanoma Res. 9 (4), 395–399 (1999).
31. Zach O, Kasparu H, Krieger O et al. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transciptase polymerase chain reaction for mammaglobin mRNA. J. Clin. Oncol. 17 (7), 2015–2019 (1999).
32. Mitas M, Mikhitarian K, Walters C et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int. J. Cancer 93 (2), 162–171 (2001).
33. Houghton RL, Dillon DC, Molesh DA et al. Transcriptional complementarity in Breast cancer: application to detection of circulating tumor cells. Mol. Diagn. 6 (2), 79–91 (2001).
34. Willeke F, Ridder R, Mechtersheimer G et al. Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications. Clin. Cancer Res. 4 (7), 1779–1784 (1998).
35. Tseng CJ, Pao CC, Lin JD et al. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J. Clin. Oncol. 17 (5), 1391–1396 (1999).
36. Kumaki F, Kawai T, Hiroi S et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum. Pathol. 32 (2), 188–195 (2001).
37. Soria JC, Gauthier LR, Raymond E et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin. Cancer Res. 5 (5), 971–975 (1999).
38. Jung R, Petersen K, Kruger W et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br. J. Cancer 81 (5), 870–873 (1999).
39. Lambrechts AC, vant Veer LJ, Rodenhuis S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann. Oncol. 9 (12), 1269–1276 (1998).
40. Eltahir EM, Mallinson DS, Birnie GD et al. Putative markers for the detection of breast carcinoma cells in blood. Br. J. Cancer 77 (8), 1203–1207 (1998).
41. de Graaf H, Maelandsmo GM, Ruud P et al. Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. Int. J. Cancer 72 (1), 191–196 (1997).
42. Krismann M, Todt B, Schroder J et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J. Clin. Oncol. 13 (11), 2769–2775 (1995).
43. Taback B, Morton DL, ODay SJ et al. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res. 15878–15892 (2001).
44. Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol. 13 (8), 2109–2116 (1995).
45. Manzotti M, DellOrto P, Maisonneuve P et al. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int. J. Cancer 95 (5), 307–312 (2001).
46. Okada Y, Fujiwara Y, Yamamoto H et al. Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer 92 (8), 2056–2064 (2001).
47. Passlick B, Pantel K. Detection and relevance of immunohistochemically identifiable tumor cells in lymph nodes. Recent Results Cancer Res. 15729–15737 (2000).
48. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86 (12), 2668–2673 (1999).
49. Bostick PJ, Morton DL, Turner RR et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol. 17 (10), 3238–3244 (1999).
50. Kataoka A, Mori M, Sadanaga N et al. RTPCR detection of breast cancer cells in sentinel lymph nodes. Int. J. Onc. 16 (6), 1147–1152 (2000).
51. Van Trappen PO, Gyselman VG, Lowe DG et al. Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet 357 (9249), 15–20 (2001).
52. Bilchik AJ, Saha S, Wiese D et al. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter Phase II trial. J. Clin. Oncol. 19 (4), 1128–1136 (2001).
53. Noguchi M, Tsugawa K, Bando E et al. Sentinel lymphadenectomy in breast cancer: identification of sentinel lymph node and detection of metastases. Breast Cancer Res. Treat. 5397–6104 (1999).
54. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res. 58 (20), 4581–4584 (1998).
55. Mori M, Mimori K, Inoue H et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptasepolymerase chain reaction. Cancer Res. 55 (15), 3417–3420 (1995).
56. Diel IJ, Kaufmann M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J. Clin. Oncol. 10 (10), 1534–1539 (1992).
57. Simmons R, Hoda S, Osborne M. Bone marrow micrometastases in breast cancer patients. Am. J. Surg. 180 (4), 309–312 (2000).
58. Weckermann D, Muller P, Wawroschek F et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J. Urol. 166 (2), 699–703 (2001).
59. Cote RJ, Beattie EJ, Chaiwun B et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann. Surg. 222 (4), 415–423 (1995).
60. Vogel I, Kruger U, Marxsen J et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin. Cancer Res. 5 (3), 593–599 (1999).
61. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J. Natl Cancer Inst. 91 (13), 1113– 1124 (1999).
62. Relihan N, McGreal G, Kelly J et al. Combined sentinel lymph-node mapping and bone-marrow micrometastatic analysis for improved staging in breast cancer. Lancet 354 (9173), 129–130 (1999).
63. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9 (10), 1749–1756 (1991).
64. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J. Clin. Oncol. 16 (2), 557–566 (1998).
65. Zippelius A, Kufer P, Honold G et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J. Clin. Oncol. 15 (7), 2701–2708 (1997).
66. Wharton RQ, Jonas SK, Glover C et al. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription- PCR assays and multiple blood samples. Clin. Cancer Res. 5 (12), 4158–4163 (1999).
67. Hardingham JE, Hewett PJ, Sage RE et al. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int. J. Cancer 89 (1), 8–13 (2000).
68. Ghossein RA, Rosai J, Scher HI et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50 (1), 100–105 (1997).
69. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 4 (2), 419–428 (1998).
70. Mellado B, Gutierrez L, Castel T et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 5 (7), 1843–1848 (1999).
71. Oefelein MG, Ignatoff JM, Clemens JQ, Watkin W, Kaul KL. Clinical and molecular follow-up after radical retropubic prostatectomy. J. Urol. 162 (2), 307–310 (1999).
72. Ko Y, Grunewald E, Totzke G et al. High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: a model for the analysis of illegitimate gene expression. Oncology 59 (1), 81–88 (2000).
73. Silva AL, Diamond J, Silva MR, Passos- Coelho JL. Cytokeratin 20 is not a reliable molecular marker for occult breast cancer cell detection in hematological tissues. Breast Cancer Res. Treat. 66 (1), 59–66 (2001).
74. Eaton MC, Hardingham JE, Kotasek D, Dobrovic A. Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. Biotechniques 22 (1), 100–105 (1997).
75. Kostler WJ, Brodowicz T, Hejna M, Wiltschke C, Zielinski C. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications and emerging therapeutic consequences. Cancer Detect. Prev. 24 (4), 376–403 (2000).
76. Naume B, Borgen E, Nesland JM et al. Increased sensitivity for detection of micrometastases in bone-marrow/ peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int. J. Cancer 78 (5), 556–560 (1998).
77. Wang ZP, Eisenberger MA, Carducci MA et al. Identification and characterization of circulating prostate carcinoma cells. Cancer 88 (12), 2787–2795 (2000).
78. Lacroix J, Becker HD, Woerner SM et al. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRPspecific RT-PCR. Int. J. Cancer 92 (1), 1–8 (2001).
79. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60 (21), 5954–5958 (2000).
80. Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am. J. Clin. Pathol. 116 (1), 79–86 (2001).
81. Sokolova IA, Halling KC, Jenkins RB et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J. Mol. Diagn. 2 (3), 116–123 (2000).
82. Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl Cancer Inst. 93 (11), 858–865 (2001).
83. Sauter ER, Ehya H, Babb J et al. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br. J. Cancer 81 (7), 1222–1227 (1999).
84. Evron E, Dooley WC, Umbricht CB et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357 (9265), 1335–1336 (2001).